Study of the Effect of Food on the Pharmacokinetics of Mirabegron
This study has been completed.
Sponsor:
Astellas Pharma Inc
Information provided by:
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT00939757
First received: July 13, 2009
Last updated: August 3, 2009
Last verified: August 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to assess the effect of food on the pharmacokinetics of a single oral dose of mirabegron in healthy male and female subjects.
| Condition | Intervention | Phase |
|---|---|---|
|
Healthy Pharmacokinetics of Mirabegron |
Drug: mirabegron |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Crossover Assignment Masking: Open Label |
| Official Title: | A Phase 1, Open-Label, Randomized, Single Oral Dose, Three-Way Crossover Study to Assess the Effect of Food on the Pharmacokinetics of Mirabegron |
Resource links provided by NLM:
Further study details as provided by Astellas Pharma Inc:
Primary Outcome Measures:
- Assess the effects of food on the pharmacokinetics of a single oral dose of mirabegron [ Time Frame: 4-5 weeks ] [ Designated as safety issue: No ]
| Enrollment: | 76 |
| Study Start Date: | May 2009 |
| Study Completion Date: | July 2009 |
| Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1. mirabegron, lower dose |
Drug: mirabegron
oral tablet
Other Name: YM178
|
| Experimental: 2. mirabegron, higher dose |
Drug: mirabegron
oral tablet
Other Name: YM178
|
Detailed Description:
Subjects will be assigned in a random order to receive 3 dosing regimens:
- a single oral dose under a fasting condition;
- a single oral dose with food (low fat breakfast);
- a single oral dose with food (high fat breakfast).
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- The subject must weigh at least 45 kg and have a body mass index (BMI) between 20.0 and 32.0 kg/m2 , inclusive
- The subject must have a normal or clinically non-significant 12 lead ECG as well as normal or clinically non-significant laboratory test results
- Female subjects must be post-menopausal (defined as at least 2 years without menses), surgically sterile, or practicing effective contraception, and will continue to use effective contraception during the study period. All females must be non-lactating, and must have a negative pregnancy test result
- The subject must have negative test results for drugs of abuse and alcohol screens
- The subject must have good venous access in both arms
Exclusion Criteria:
- The subject has evidence of QTc interval >430 msec for male, >450 msec for female
- The subject has liver function test values (ALT, AST, or bilirubin) above the upper limit of normal
- The subject has a history or presence of psychiatric illness, serious active or recurrent infection, or any medical condition or disorder that precludes the subject from participating in the study
- The subject has a previous history of cancer other than basal cell carcinoma or Stage 1 squamous cell carcinoma that has not been in remission for at least 5 years
- The subject has donated or lost ≥ 450 mL blood within 56 days prior to study drug administration or has donated plasma within 7 days prior to study drug administration
- The subject has received or is anticipated to receive a prescription drug within 14 days prior to Day -1 of Period 1 (within 30 days 1 for any long acting treatments such as depot formulations). Subject has taken any over-the-counter (OTC) medications, including complementary and alternative medicines (except for oral contraceptives and occasional use of acetaminophen of up to 2000 mg/day but not more than 4 days per week) within 14 days
- The subject has consumed alcohol, xanthine derivative-containing food/beverages (tea, chocolate), grapefruit juice, grapefruit-containing products or Seville oranges (e.g., bitter marmalade) within 48 hours before admission into the unit
- The subject has used tobacco-containing products and nicotine-containing products within 6 months
- The subject consumes more than 5 units of alcoholic beverages (one unit is 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits) per week, or has a history of substance abuse, drug addiction, or alcoholism within past 2 years
- The subject is known to have hepatitis or HIV-1 and/or HIV-2, or is positive for hepatitis A antibody IgM, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody
Contacts and Locations
More Information
No publications provided by Astellas Pharma Inc
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Sr Manager Clinical Trials Registry, Astellas Pharma Global Development |
| ClinicalTrials.gov Identifier: | NCT00939757 History of Changes |
| Other Study ID Numbers: | 178-CL-041 |
| Study First Received: | July 13, 2009 |
| Last Updated: | August 3, 2009 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Astellas Pharma Inc:
|
Healthy volunteer subjects pharmacokinetics YM178 mirabegron food |
ClinicalTrials.gov processed this record on May 22, 2013